European Journal of Neurology· 2017Q1· Review

Huntington's disease: a clinical review

Peter McColgan, Sarah J. Tabrizi

1,095citations
Q1SCImago
2017year

Short summary

Emerging therapies, particularly antisense oligonucleotides, show promise for lowering mutant huntingtin levels, potentially offering the first disease-modifying treatment for Huntington's disease.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Cellular and Molecular Neuroscience

Cellular and Molecular NeuroscienceNeuroscience